<DOC>
	<DOC>NCT02932267</DOC>
	<brief_summary>This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face. All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump Forte) once daily on whole face. The purpose of this trial is to evaluate subject reported outcomes with the combination of Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (IV to VI).</brief_summary>
	<brief_title>Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined by: 1. Investigator's Global Assessment (IGA) score of 3 (Moderate) OR 4 (Severe ); and 2. A minimum of 25100 inflammatory lesions (papules and pustules); and 3. A minimum of 30150 noninflammatory lesions (open and closed comedones) in total (excluding the nose); and 4. No more than two acne nodules (â‰¥ 1 cm), Subject with skin phototype IV to VI on Fitzpatrick skin phototype scale, Subjects from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/AfricanAmerican, Subject with acne conglobata, acne fulminans, secondary acne (chloracne, druginduced acne, etc.), nodulo cystic acne, acne requiring systemic treatment, Subject with history of lupus, atopic dermatitis, perioral dermatitis, dermatomyositis, rosacea Female subject who is pregnant, lactating or planning a pregnancy during the trial, Subjects having received at least one of the following topical treatments on the treated area: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone, hydroxyacids, Zinc containing treatments, antiseptics, other antiinflammatory products or other acne treatments (2 weeks); Retinoids (4 weeks); Cosmetic/aesthetic procedures on the face (1 week); Wax epilation (2 weeks); Photodynamic therapy (6 weeks); Laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne (3 months). Subjects having received at least one of the following systemic treatments: Corticosteroids, tetracyclines, other antibiotics (except penicillin) (1 month); Oral retinoids/isotretinoin/ antiandrogens / Cyproterone acetate / Chlormadinone acetate (6 months); Spironolactone/ Drospirenone (3 months); Immunomodulators (3 months) and Oral contraceptives/ oral dapsone for acne(1 month).</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acne</keyword>
	<keyword>Dark skin</keyword>
</DOC>